Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis

Sarah A. Buckley, Brent L. Wood, Megan Othus, Christopher S. Hourigan, Celalettin Ustun, Michael A. Linden, Todd E. DeFor, Michele Malagola, Chloe Anthias, Veronika Valkova, Christopher G. Kanakry, Bernd Gruhn, Francesco Buccisano, Beth Devine, and Roland B. Walter

Disclosures: C.S.H. receives research funding from SELLAS Life Sciences Group AG. M.A.L. is a consultant to Bristol Myers Squibb and receives royalties from Cell Signaling Technology.

Contributions: S.A.B. and R.B.W. were responsible for the concept of this meta-analysis and contributed to the literature search, data collection quality assessment, data analysis and interpretation, and writing of the manuscript. B.L.W. provided guidance on the risk of bias assessment, analyzed and interpreted data, and revised the manuscript. M.O. and B.D. provided guidance on statistical methodology, analyzed and interpreted data, and revised the manuscript. C.S.H, C.U., M.A.L., T.E.D., M.M., C.A., V.V., C.G.K., B.G., and F.B. contributed data, analyzed and interpreted data, and revised the manuscript.